Agenus Inc. announced new translational and clinical biomarker findings from its Phase 1b C-800-01 trial (NCT03860272) evaluating botensilimab (an Fc-enhanced anti-CTLA-4 antibody) in combination with balstilimab (an anti-PD-1 antibody) in advanced, treatment-refractory cancers, including microsatellite-stable metastatic colorectal cancer (MSS mCRC). The company reported outcomes in 341 efficacy-evaluable patients with available biomarker data (cutoff Dec. 13, 2025), including an objective response rate of 17%, a clinical benefit rate of 26%, and a median overall survival of 17.2 months, and described analyses integrating blood-based inflammation markers with tumor immune features to stratify survival in MSS mCRC. The data were presented at the AACR Immuno-Oncology Conference in Los Angeles.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602191515BIZWIRE_USPR_____20260219_BW390538) on February 19, 2026, and is solely responsible for the information contained therein.